European perspective on the costs and cost-effectiveness of cancer therapies.
about
When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncologySafety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials.Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice.Cancer incidence and mortality in the Greater Poland Region-Analysis of the year 2010 and future trends.Does adjusting for health-related quality of life matter in economic evaluations of cancer-related interventions?Cost-effectiveness of adding cetuximab to platinum-based chemotherapy for first-line treatment of recurrent or metastatic head and neck cancer.Antioxidant, Anti-inflammatory, and Genomic Stability Enhancement Effects of Zinc l-carnosine: A Potential Cancer Chemopreventive Agent?International comparison of the factors influencing reimbursement of targeted anti-cancer drugs.Comparing cancer mortality and GDP health expenditure in England and Wales with other major developed countries from 1979 to 2006.Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in malaysia."Well, I think there is great variation...": a qualitative study of oncologists' experiences and views regarding medical criteria and other factors relevant to treatment decisions in advanced cancer.Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.Treatment of metastatic breast cancer: second line and beyond.Advances in cancer therapeutics and patient access to new drugs.Review of the economic evaluations of hormonal therapy for patients with locally advanced prostate cancer.Health systems performance and cancer outcomes.Market access of cancer drugs in European countries: improving resource allocation.Inventory of economic evaluation of head and neck oncology from the German perspective.What is a new drug worth? An innovative model for performance-based pricing.Health technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the United States take notice?Bevacizumab in recurrent, persistent, or advanced stage carcinoma of the cervix: is it cost-effective?Cost-Utility Analysis of Cancer Prevention, Treatment, and Control: A Systematic Review.The lawsuits to antineoplastic drugs: the tip of an iceberg?Is the EQ-5D suitable for use in oncology? An overview of the literature and recent developments.The Pharmacological Costs of Complete Liver Resections in Unselected Advanced Colorectal Cancer Patients: Focus on Targeted Agents. A Review of Randomized Clinical Trials.Evidence for distinct mechanisms of uptake and antitumor activity of secretory phospholipase A2 responsive liposome in prostate cancer.Adoption of trastuzumab for breast cancer in four emerging countries in the use of health technology assessment: a case study.Integrating value assessment into discussions about the price of cancer drugs.Costs and concerns in cancer care.Challenges in organizing effective oncology service: inter-European variability in the example of head and neck cancers.A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs.Trends in annual drug expenditure – a 16 year perspective of a public healthcare maintenance organization.Trends in annual drug expenditure - a 16 year perspective of a public healthcare maintenance organization.The European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) applied to pivotal phase III randomized-controlled trials of tyrosine kinase inhibitors in first-line for advanced non-small cell lung cancer with activating eReal-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-targeted treatment to imatinib.The costs of care in haematological cancers: Health economic issues.The Economic Attractiveness of Targeted Radiotherapy: Value for Money?
P2860
Q24645229-5073908E-5ACF-4C66-963A-3E235C6EEC7CQ33392652-E6E903CB-18EF-4717-9C6E-03B51F49FDCDQ33895530-6D357687-14A9-4889-984F-B6C1DE301A68Q34112799-41447985-7024-4199-86C6-F95DAA0D15CBQ34166892-00806EF0-D4A1-4194-BC4C-CEA221685D22Q34321100-34622B37-0752-4F23-B3FE-91A15E6BB90FQ34549429-0225A812-C8EE-407C-AE0A-5D6CC359606DQ34643295-116BF4F4-3DFD-4CD4-ACE0-547D4E3A5206Q35623274-FB5057CD-78BD-45BE-9592-AC1A281DC307Q35895807-FE5D05B1-16B0-4AB9-AF64-EC16028C2621Q36565670-7B7BAEDC-4F04-4498-A407-6DD24F0C7B41Q37293688-26DAF15E-5322-4DF3-B1B1-02CA9D1C644CQ37802108-2A0150A5-AAE6-4C62-9AAD-09BFB83ACC2DQ37823895-14C9A7B7-27DD-4ECB-905F-04E944ADF616Q38097531-0BE1C47F-CC8A-4CF3-9840-658D543FDEA2Q38130362-E9C5DF6A-C154-4EB3-8FA1-0BFC232DCFBDQ38163486-BC43FCF1-6DDD-42A2-A1D2-9A5D3A3A73B2Q38176769-663D1F0A-83D4-4190-A0A3-05018C12780BQ38254384-21A8A679-A0B8-440B-BE9F-AAE260903096Q38255974-650727DE-27FF-4ADE-9984-D99184923E8DQ38302729-986B521C-E16F-45FD-B913-90C56A3C72F3Q38608095-515F24E2-233F-42DA-86C8-3E3C6F122F7DQ38632181-430615F1-640A-4485-A13B-3B2CFAA392CDQ38710744-4FF70BF2-12DB-4287-8313-1274A6BD0ECAQ38917649-BA269E05-EE81-4144-A2D1-F1338CC1B1ABQ39297921-174140C0-BBE1-48BB-8080-26474F076066Q39664372-07BCDB2D-21A3-42FD-B0F0-A3885CBD6625Q42337498-91A9F272-0196-40A0-80A0-E9C660ED27E3Q42380073-B23828A4-9120-49A2-A4FE-9D4D819B20E6Q42761595-BF6E97B4-1373-4BF8-BDE7-004D3CD41692Q44008750-3F42C35A-9F0E-4095-9EA7-5B3A09E7D115Q45834927-80D75B38-1BDC-401F-8943-2787165E7B9AQ49329447-266A3649-A615-4570-8DAB-3BCB02E63139Q51320122-335D70B1-477B-4682-9106-F57DFDF7E096Q51334797-51C008E8-4BAB-46E3-B165-91D5B4696198Q53026370-93FF7349-60E1-4C2C-8C77-3D39EE49B45AQ53726144-EB64E27B-CBE3-487E-8E4E-7A8D74C6EA90Q58758454-3ECCCA23-B1A0-4A3A-BF6B-30C99A62EDCD
P2860
European perspective on the costs and cost-effectiveness of cancer therapies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
European perspective on the costs and cost-effectiveness of cancer therapies.
@ast
European perspective on the costs and cost-effectiveness of cancer therapies.
@en
type
label
European perspective on the costs and cost-effectiveness of cancer therapies.
@ast
European perspective on the costs and cost-effectiveness of cancer therapies.
@en
prefLabel
European perspective on the costs and cost-effectiveness of cancer therapies.
@ast
European perspective on the costs and cost-effectiveness of cancer therapies.
@en
P356
P1476
European perspective on the costs and cost-effectiveness of cancer therapies.
@en
P2093
Anne R Mason
Michael F Drummond
P304
P356
10.1200/JCO.2006.07.8956
P407
P577
2007-01-01T00:00:00Z